预防性脑照射在广泛期小细胞肺癌中的作用:系统评价与荟萃分析
该系统评价与荟萃分析纳入5项研究共984例广泛期小细胞肺癌患者,其中448例接受预防性脑照射(PCI),536例未接受。汇总分析显示PCI未显著改善总生存(HR=0.82,95%CI 0.60-1.11,P=0.19),但1年生存率(37.1%对27.1%)、无进展生存(HR=0.83,95%CI 0.70-0.98,P=0.03)和脑转移风险(HR=0.34,95%CI 0.23-0.50,P<0.001)均显著获益。
要点
- PCI未显著改善广泛期小细胞肺癌患者的总生存。
- PCI显著提高1年生存率(37.1%对27.1%)。
- PCI显著降低脑转移风险并改善无进展生存。
核心结论
- PCI在广泛期小细胞肺癌中虽未显著改善总生存,但可显著改善1年生存、无进展生存并降低脑转移风险。
研究设计与样本
- 系统评价与荟萃分析,遵循PRISMA指南,检索MEDLINE、EMBASE和Cochrane Central Register。
- 共纳入5项研究984例患者,448例接受PCI,536例未接受PCI。
主要发现
- PCI组与对照组的总生存无统计学差异(HR=0.82;95%CI 0.60-1.11;I2=77%;P=0.19)。
- PCI组1年生存率显著优于无PCI组(37.1%对27.1%;RR=0.87;95%CI 0.80-0.95;I2=47%;P=0.002)。
- PCI组无进展生存显著获益(HR=0.83;95%CI 0.70-0.98;I2=22%;P=0.03)。
- PCI组脑转移风险显著降低(HR=0.34;95%CI 0.23-0.50;I2=0%;P<0.001)。
临床怎么用
- 对于广泛期小细胞肺癌患者,PCI可考虑用于改善1年生存、无进展生存并降低脑转移风险,但需权衡总生存未获益及异质性。
局限性
- 纳入研究间总生存分析存在显著异质性(I2=77%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The role of prophylactic cranial irradiation (PCI) is controversial in patients with extensive stage small cell lung cancer. The aim of this study was to determine the impact of PCI in these patients. METHODS: We performed a systematic review and meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. A systematic literature search was conducted in MEDLINE, EMBASE, and the Cochrane Central Register. The primary outcome was overall survival (OS). RESULTS: We identified five studies comprising 984 patients, of whom 448 received PCI and 536 did not receive PCI. In pooled estimates, PCI did not statistically improve OS compared with controls (hazard ratio [HR] = 0.82; 95% confidence interval [CI]: 0.60-1.11; I2 = 77%; p = 0.19). However, the PCI group had a significant advantage in 1-year survival compared to the no-PCI group (37.1% versus 27.1%; risk ratio = 0.87; 95% CI: 0.80-0.95; I2 = 47%; p = 0.002), and the pooled estimates indicated that progression-free survival and the risk of brain metastasis were associated with significant benefit in the PCI group (HR = 0.83; 95% CI: 0.70-0.98; I2 = 22%; p = 0.03; and HR = 0.34; 95% CI: 0.23-0.50; I2 = 0%; p < 0.001, respectively). CONCLUSIONS: Our findings suggest that PCI in patients with extensive stage small cell lung cancer may lead to a significant benefit in 1-year survival, progression-free survival, and the risk of brain metastasis, despite the lack of a significant advantage in OS.
引用
- Maeng CH, Song JU, Shim SR, et al. The Role of Prophylactic Cranial Irradiation in Patients With Extensive Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2018. PMID: 29526825. doi:10.1016/j.jtho.2018.02.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。